

Resource Summary Report

Generated by [kravitz2](#) on Jul 31, 2026

Crl:CD1-Foxn1^{NU}

RRID:IMSR_CRL:086

Type: Organism

Proper Citation

RRID:IMSR_CRL:086

Organism Information

URL: <http://www.criver.com/products-services/basic-research/find-a-model/cd-1-nude-mouse>

Proper Citation: RRID:IMSR_CRL:086

Description: Mus musculus with name Crl:CD1-Foxn1^{NU} from IMSR.

Species: Mus musculus

Notes: gene symbol note: ; inbred strain:

Catalog Number: CRL:086

Database: Charles River Laboratories

Database Abbreviation: CRL

Availability: live

Organism Name: Crl:CD1-Foxn1^{NU}

Record Creation Time: 20250513T062409+0000

Record Last Update: 20260725T053145+0000

Ratings and Alerts

No rating or validation information has been found for Crl:CD1-Foxn1^{NU}.

No alerts have been found for Crl:CD1-Foxn1^{NU}.

Data and Source Information

Source: [Integrated Animals](#)

Source Database: Charles River Laboratories

Usage and Citation Metrics

We found 338 mentions in open access literature.

Listed below are recent publications. The full list is available at [kravitz2](#) .

Wallimann RH, et al. (2025) Preclinical comparison of (radio)lanthanides using mass spectrometry and nuclear imaging techniques: biodistribution of lanthanide-based tumor-targeting agents and lanthanides in ionic form. *European journal of nuclear medicine and molecular imaging*, 52(4), 1370.

Cammareri P, et al. (2025) Loss of colonic fidelity enables multilineage plasticity and metastasis. *Nature*, 644(8076), 547.

Sarkar S, et al. (2025) A biorthogonal chemistry approach for high-contrast antibody imaging of lymphoma at early time points. *EJNMMI research*, 15(1), 26.

Alshuhri MS, et al. (2025) MRI Delta Radiomics to Track Early Changes in Tumor Following Radiation: Application in Glioblastoma Mouse Model. *Biomedicines*, 13(4).

Ramírez-Ruiz F, et al. (2025) Polycaprolactone for Hard Tissue Regeneration: Scaffold Design and In Vivo Implications. *Bioengineering (Basel, Switzerland)*, 12(1).

Roulstone V, et al. (2025) Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasion. *Nature communications*, 16(1), 4855.

Sun X, et al. (2025) Placenta-derived trophoblast extracellular vesicles promote CD169+ macrophage migration and suppress ovarian tumour growth. *Journal of translational medicine*, 23(1), 1295.

Carrieri L, et al. (2025) Proteoglycan-4 potentiates the antitumor efficacy of regorafenib in an orthotopic model of hepatocellular carcinoma. *Journal of experimental & clinical cancer research : CR*, 45(1), 7.

Martin G, et al. (2025) Niclosamide and Palbociclib Act Synergistically to Reduce Cholangiocarcinoma Cell Viability In Vitro and Inhibit Tumour Growth in a Mouse Model. *Cancers*, 17(22).

Simões-Sousa S, et al. (2025) ARID1A stabilizes non-homologous end joining factors at DNA breaks induced by the G4 ligand pyridostatin. *Cell reports*, 44(9), 116277.

Kyula-Currie J, et al. (2025) The PARP inhibitor talazoparib synergizes with reovirus to induce cancer killing and tumour control in vivo in mouse models. *Nature communications*, 16(1), 6299.

Rossmann JM, et al. (2025) Targeting the Met-RIPK1 signaling axis to enforce apoptosis and necroptosis in colorectal cancer. *Cell death & disease*, 16(1), 733.

Al-Mubarak H, et al. (2025) Using Delta MRI-Based Radiomics for Monitoring Early Peritumoral Changes in a Mouse Model of Glioblastoma: Primary Study. *Cancers*, 17(21).

Senatore E, et al. (2025) Praja2 controls P-body assembly and translation in glioblastoma by non-proteolytic ubiquitylation of DDX6. *EMBO reports*, 26(9), 2347.

Hunkeler BD, et al. (2025) Evaluation of folate receptor-alpha and other surface markers as potential targets for radionuclide therapy of ovarian cancer. *EJNMMI research*, 15(1), 144.

Han Y, et al. (2025) TGF- β 1-based restoration of sodium iodide symporter expression in radioiodine-refractory differentiated thyroid cancer via engineered MSCs. *Molecular therapy : the journal of the American Society of Gene Therapy*, 33(12), 6130.

Hockings H, et al. (2025) Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control. *Cancer research*, 85(18), 3503.

Rizzo LY, et al. (2025) Analysis of nanomedicine primary tumor vs. metastasis targeting using clinical-stage core-crosslinked polymeric micelles. *Cell reports*, 44(8), 116086.

Gentili C, et al. (2024) Sustainably cultured coral scaffold supports human bone marrow mesenchymal stromal cell osteogenesis. *Regenerative therapy*, 26, 366.

Wirth F, et al. (2024) Insights into the metastatic bone marrow niche gained from fibronectin and α 1 integrin transgenic mice. *Neoplasia (New York, N.Y.)*, 58, 101058.